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In the confocal mode, Raman microspectroscopy can profile the biochemical content of biological cells at a 
subcellular level, and any changes to it by exogenous agents, such as therapeutic drugs or toxicants. As an exploration 
of the potential of the technique as a high content, label free analysis technique, this report reviews work to monitor 
the spectroscopic signatures associated with the uptake and response pathways of commercial chemotherapeutic 
agents and polymeric nanoparticles by human lung cells. It is demonstrated that the signatures are reproducible and 
characteristic of the cellular event, and can be used, for example, to identify the mode of action of the agent as well 
as the subsequent cell death pathway, and even mechanisms of cellular resistance. Data mining approaches are 
discussed and a spectralomics approach is proposed. 
OCIS codes: (170.5660) Raman spectroscopy, (180.5655) Raman microscopy, (170.1530) Cell analysis, (170.1580) Chemometrics.  
http://dx.doi.org/10.1364/AO.99.099999 
1. INTRODUCTION 
The application of Raman spectroscopy to biomolecules and 
even tissues was first demonstrated as early as the 1960s[1-3] 
and by the mid-1970s biomedical applications were explored[4]. 
Whole cell and tissue studies have been carried out on a range of 
pathologies[5-9] and in vivo studies[10-12] have demonstrated 
the prospective for diagnostic applications. The potential of 
vibrational spectroscopy in conjunction with multivariate 
analysis techniques as a diagnostic tool has thus been well 
demonstrated and the concept of Spectral Cytopathology has 
been coined[13]. However, since the original claims in the 1990s, 
clinical translation has been slow, potentially due to demands of 
large scale clinically relevant studies and the rigours of 
legislative approval, prompting an appraisal of more realistic 
strategically achievable targets for the field[14]. Importantly, the 
intrinsic strength of spectroscopy is in materials and process 
analysis rather than classification, and in vitro studies of cells 
allow a detailed analysis of the fundamental cell biology, or 
biochemical changes, for example as a result of an external 
agonist, toxicant or chemotherapeutic agent[15-17]. The 
technique is label free, and, in the case of Raman 
microspectroscopy, subcellular analysis can be performed in the 
confocal microscopic mode, providing high content 
spectroscopic signatures of biochemical profiles, promising 
potentially more realisable applications in fundamental cellular 
(cytological) research, medicinal chemistry and 
pharmacological/toxicological screening. Regulatory 
requirements in both the EU and US (EU Directive-2010/63/EU 
and US Public Law 106-545, 2010, 106th Congress) have 
increasingly restricted the use of animal models for 
development of pharmaceuticals and cosmetics, and Raman 
microspectroscopy offers a potentially low cost, label free 
alternative to in vitro High Content Analysis for routine 
screening.[18, 19] 
This paper reviews recent work carried out at the Dublin 
Institute of Technology, to advance Raman microspectroscopy 
for cellular and subcellular analysis, probing the limitations of 
the technique in terms of reproducibility and specificity of 
spectral signatures of subcellular events and pathways. 
Specifically, it explores the areas of (A) Cellular differentiation 
(B) Drug screening and (C) Nanotoxicological screening. As 
models, the responses elicited by established and commercially 
available chemotherapeutic agents and nanoparticle standards 
in commercially available in vitro cell lines are chosen. The often 
subtle spectroscopic changes associated with the cellular 
perturbations are elucidated using a range of multivariate data 
mining techniques, and the challenge of identifying consistent 
reproducible label free spectral markers is addressed. 
2. EXPERIMENTAL 
 
The details of experimental methods and protocols are described in 
the original publications[20-23], but are summarised here. 
A. Materials 
 
A549 human lung adenocarcinoma cells with the alveolar type II 
phenotype were obtained from ATTC (Manassas, VA, USA) and Calu-1 
human lung epidermoid carcinoma cells were obtained from the 
European Collection of Cell Cultures. 
Doxorubicin hydrochloride® powder (Sigma Life Sciences, Ireland) 
was diluted in 1mL sterile water to the required concentration, 
identified by cytotoxicological assays.  
40 nm non-toxic carboxyl-modified polystyrene nanoparticles 
(PSNPs) were employed to determine nanoparticle localisation and 
trafficking, whereas 100 nm toxic amine-modified polystyrene 
nanoparticles (PS-NH2) were used to determine spectral markers of the 
toxicity. Generation 5 PAMAM dendrimers were used as a secondary 
toxic nanoparticle model for comparison of spectral markers of toxicity. 
All nanomaterials were purchased from Sigma-Aldrich (Ireland). 
B. Cell Culture 
 
A549 cells were cultured in DMEM (with 2 mM L-glutamine) with 
10 % foetal bovine serum (FBS) and Calu-1 cells in RPMI with 10% FBS, 
both at 37°C in a humidified atmosphere containing 5% CO2 and cells 
were split every two days to maintain ~60% confluence. 
C. Raman Microspectroscopy 
 
Cells (~ 3 x 103/cm2) were seeded and incubated on (20mm 
diameter) CaF2 windows (Crystan Ltd, UK) for 24 hrs for both control 
and exposure to chemotherapeutic drug or nanoparticles. Medium was 
then removed and samples were rinsed twice with sterile PBS and 
covered with solutions of the appropriate drug solution or nanoparticle 
suspension concentration. After each incubation period cells were 
washed twice with sterile PBS and fixed in formalin (10 %, 15 min). 
A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a 785 nm, 
300 mW diode laser as source, Peltier cooled 16-bit CCD, 300 lines/mm 
grating and 100 μm confocal hole, was used for this work. Cells were 
measured either air dried or in water immersion, and spectra were 
acquired from the three cell locations: cytoplasm, nuclear and nucleolar 
in the range from 400 cm-1 to 1800 cm-1 with an x100 objective 
(LCPlanN, Olympus (dry), or LUMPlanF1, Olympus (immersion)) for 30 
s two times, to finally produce a data set of 30 points per cell location for 
each cell line, over a total of 90 different cells. 
D. Data Processing and Analysis 
 
Raman spectral pre-processing and analysis were performed in 
Matlab using algorithms developed in house. Prior to analysis, 
background was subtracted using a NCLS (non-negatively constrained 
least squares) algorithm, spectra were smoothed (Savitsky-Golay filter 
3th order, 11 points), baseline corrected (fifth order polynomial) and 
vector normalised. 
Principal components analysis (PCA) was employed as an 
unsupervised multivariate approach to analyse data and the effects of 
the drug or nanoparticles in each cell localisation. The order of the PCs 
denotes their importance to the dataset and PC1 describes the highest 
amount of variation.  
Partial least squares regression (PLSR), a statistical regression 
technique which reduces the dimensionality of the data and correlates 
information, here represented by the Raman spectra, to values of the 
drug concentration inside the cells, and the time evolution, was 
employed to track the temporal and dose dependent evolution of the 
spectral signatures in the subcellular regions. The percentage of 
variance explained as a function of the number of components was 
calculated using 10-fold cross validation and from a plot of the percent 
of variance explained as a function of number of components, the 
majority percentage of variance (above 90%) was found to be explained 
by the first 3 components. 
The regression coefficients obtained by PLSR of Raman data 
regressed separately against drug cellular concentration and time 
evolutions were plotted and analysed. As a function of frequency, the co-
efficients illustrate the spectral features which are influenced by the 
intracellular interaction of the drug and the resulting metabolic changes. 
3. Results 
A. Cellular differentiation 
 
Raman spectra were taken from the three cellular regions for all cell 
lines and Figure 1 shows the average spectra corresponding to each cell 
region, for the example of A549 cells [20]. Visibly, it can be seen that the 
mean spectra of the nucleolar, nuclear and cytoplasmic regions are 
somewhat different, and discriminating peaks (indicated by highlighted 
regions in Figure 1) at, for example, 1578, 1095, 830 and 795 cm-1 can 
be assigned to nucleic acids, corresponding respectively to vibrations of 
the DNA bases adenine and guanine, DNA PO2- symmetric stretching, 
ribose phosphate and DNA backbone O-P-O stretching, [24, 25] while 
others at 1300 (CH deformation) and 717 cm-1 (CN+(CH3)3 stretching) 
are associated with lipid components of the cell membrane, which are 
also observable in the spectra of the nuclear and nucleolar regions, 
although more prominently in the spectra of the cytoplasmic region. 
The DNA bands at 1095 cm-1 and 830 cm-1 indicate that the DNA is in 
the B form, while the peak at 813 cm-1 corresponds to DNA A form.[26]  
 
 
Fig. 1.  Mean spectra of A. Nucleolus, B. Nucleus and C. Cytoplasm 
of A549 cell line. Highlighted regions correspond to DNA/RNA 
and lipids features.[20] 
 
For a more detailed understanding of the differences in 
spectral profiles of the subcellular regions, a multivariate 
analysis is more informative, and therefore, PCA was employed 
to analyse and compare the spectral profiles of the subcellular 
regions as well as the differences between cancer and normal 
cell lines. Figure 2 shows the PCA scatter plot of the cytoplasmic, 
nuclear and nucleolar spectra of the Calu-1 cell line, along with 
the corresponding loadings of PC1 and PC2. PC1 clearly 
differentiates between the cytoplasmic and integrated nuclear 
regions (nuclear and nucleolar) and, according to the 
corresponding loading (loading 1), the most visible discriminant 
features derive from DNA, 795 cm-1 and 1095 cm-1, related to B-
DNA O-P-O backbone stretching and PO2- symmetric stretching, 
and lipids at 717 (CN+(CH3)3 stretching), 1300 (CH2 stretching) 
and 1440 cm-1 (CH stretching). The differentiation of the 
subcellular regions according to PC1 is not unexpected, due to 
the significant biochemical differences between the combined 
nuclear and cytoplasmic regions which are similar for all cell 
lines. The nuclear and nulceolar regions can be differentiated by 
a further, pairwaise PCA of the two subcellular regions.[20] 
Notably, a similar differentiation between the subcellular 
regions of A549 cells can be performed, and the differentiating 
PC loadings are almost identical to those of Calu-1 (Figure 2C). 
In fact, although they are relatively well distinguished from 
normal cell lines, differentiation between cancer cell lines is only 
achievable by comparison of the nucleolar regions.[22] 
Critically, the similarities of the differentiating subcellular 
spectral profiles for different cell lines supports the consistency 
and robustness of the technique for subcellular analysis. 
 
 
Fig. 2.  PCA of nucleolus, nucleus and cytoplasm in immersion conditions A. Calu-1 cell line : Cytoplasm    Nucleus     Nucleolus     B. Calu-
1 differentiating PC loadings C. A549 differentiating PC loadings [20]
B. Drug screening 
 
Raman microspectroscopy has attracted considerable 
attention over the last few years in the pharmaceutical field to 
aid in areas such as the drug discovery process, quality control 
during industrial manufacturing and detection of counterfeit 
products,[27-29] as well as its possible clinical applications.[30, 
31] Its potential as a screening technique either for normal and 
cancer cell discrimination or in chemotherapeutic and cellular 
process screening has been demonstrated.[32] 
Doxorubicin (DOX), a non cell cycle specific 
chemotherapeutic agent, is one of the two first anthracycline 
antibiotics isolated from Streptomyces peucetius[33] and 
among the most widely used chemotherapeutic agents, despite 
its numerous side effects,[34, 35] and is highly effective in 
treating different types of cancers, from leukaemia, thyroid, and 
lung to many other neoplasia, especially metastatic and invasive 
ones.[36-38] The accepted mechanisms of action of DOX are 
complex and not fully understood. They include interactions 
within the cell nucleus, consisting of DNA intercalation, cross-
linking, binding and alkylation, inhibition of topoisomerase I and 
II and RNA polymerase, all inducing DNA damage, inhibition of 
DNA replication and protein synthesis (rRNA transcription 
inhibition), as a consequence, leading to nucleolar disruption 
and cellular apoptosis[39]. DOX also interacts with the cell 
membrane and mitochondria, resulting in generation of reactive 
oxygen species leading to direct membrane damage and 
oxidative stress, responsible for the major DOX side effect, 
cardiomyopathy.[35, 40-42] DNA remains the main target of 
cancer therapeutics, whereby induction of DNA damage initiates 
a cascade of events that determines cellular apoptosis. DNA 
damage level and repair, by expression of anti-apoptotic 
proteins such as bcl-2 and resistance to apoptosis, are the main 
processes involved in carcinogenesis and in the response of 
cancer cells to cancer chemotherapy.[43]  
A. B. 
    
Fig. 3. A. Structure of Doxorubicin B. Raman spectrum of in 
aqueous solution indicating strong DOX marker bands.[21] 
To demonstrate the potential of Raman microspectroscopy 
to monitor the uptake of chemotherapeutic agents, to track the 
drug pathway and monitor cellular responses, Raman profiles 
from the three subcellular compartments, nucleolus, nucleus 
and cytoplasm, were analysed as a function of time after 
exposure of cell cultures to DOX sulutions. The anthracycline 
structure of DOX (Figure 3A), consisting of a conjugated 
anthraquinone ring structure banded to an aminoglycoside[44], 
renders it fluorescent and gives it a strong Raman scattering 
efficiency even off resonantly, (Figure 3B).  
The characteristic spectral profile of DOX can be easily 
identified superimposed on that of the exposed cell lines, and 
Figure 4A shows the sucellular uptake of DOX in the A549 and 
Calu-1 cell lines, as represented by the characteristic band at 465 
cm-1 [21] There is a progressive increase of DOX intracellular 
concentration until a plateau is reached after 6-12 hrs exposure 
and DOX is seen to accumulate in the nucleolus first, then in the 
nucleus and after 24-48 hrs appears in the cytoplasm. The 
behaviour is consistent with saturation of nuclear binding sites 
after a certain time and any additional drug taken up by cells 
accumulates in the cytoplasm.[45, 46] Interestingly, the 
accumulation rates are substantially different for the two cell 
lines investigated. Simultaneously, the characteristic cellular 
features of the subcellular regions can be tracked, as shown in 





Fig. 4. A. Evolution of DOX, represented by the Raman band at 
465 cm-1, as a function of time for the A549 and Calu-1 cell line 
for each cellular compartment, nucleolus, nucleus and 
cytoplasm. B. Evolution of selected DNA and RNA features as 
function of time. Intensities are expressed as percentage 
according to the maximum value over the three cellular 
compartments for each cell line and standard deviation 
corresponds to the spectral variations of the Raman band over 
the 30 measurements per location. [49, 50] 
Multivariate PLSR can be employed to profile the spectrum 
of the initial binding interactions of the drug in the subcellular 
regions, and the subsequent cellular responses of the cells, in the 
plateau regions. There is a striking similarity between the 
responses of the different cell-lines to the same drug, and indeed 
of the cell lines to drugs of similar mode of action, as 
demonstrated for Actinomycin D (Act), a commonly employed 
anthracyclic chemotherapeutic agent which is similar in 
molecular structure and mode of action to DOX.(47) Comparing 
the spectroscopic signatures with the commonly clinically 
employed chemotherapeutic agents Cisplatin (Cisp) and 
Vincristine (Vinc), there is a remarkable consistency of 
spectroscopic signatures of nucleic acids in the nuclear regions, 
as shown in Figure 5.(48) 
 
Fig. 5. Regression coefficients obtained by PLSR analysis for the 
A549 cell line as a function of drug dose for chemotherapeutic 
drugs DOX, Cisp (nucleus) and Vinc (nucleus). [50]  
The study of the intracellular localization of DOX demonstrates 
that the primary subcellular target is in fact the nucleolus, in 
which it interacts strongly with the RNA. Using confocal 
microscopy, upon DOX exposure, the nucleoli of the cell appear 
dark, however, indicating that the characteristic fluorescence of 
DOX is quenched in this dense subcellular region. Therefore, 
Raman microspectroscopy sheds light on the cellular 
interactions and medicinal chemistry, in situ, which were not 
previously known. In the case of the structurally similar ACT, the 
cytotoxicologically relevant dose is so low that neither the 
fluorescence not the characteristic Raman signature can be 
traced at a cellular level. Nevertheless, the initial binding 
interactions of the drug within the nucleolus and nucleus of the 
cell can be identified, associating them with the similar mode of 
action of intercalation as DOX. The timescales of the responses 
are significantly slower, however, in both cell lines, which can be 
understood in terms of the different intracellular trafficking 
processes associated with the bulky polypeptide sidechains of 
ACT, compared to DOX. Raman microspectroscopy also 
demonstrates that, although Cisp and Vinc are reported to have 
different modes of action, as alkylating agents and microtubule 
binders, respectively, their Raman signatures evolve from low to 
high doses. At doses above their median inhibitory 
concentrations, the signatures also exhibit characteristics of 
intercalation, as shown DOC and ACT, indicating that they can 
have multiple modes of action.[48] 
Monitoring the time evolution of drug distribution within the 
cell, the spectroscopic signatures of the chemical interaction in 
the subcellular regions can be identified, and associated with the 
characteristic modes of action of the drug. The signatures are 
consistent for drugs of similar modes of action, and thus can be 
exploited as a rapid in vitro tool for pre-screening of candidate 
drugs and a guide to design strategies for chemotherapeutics. 
The subsequent evolution of the spectroscopic signatures can 
then be associated with the cellular response pathways. Clear 
differences can be seen in the response pathways of the A549 
and Calu-1 cell-lines,[47] as evidenced in the univariate analysis 
of Figure 4B. PLSR analysis, and correlation with assays to probe 
the generation of anti-apoptotic proteins and DNA repair, as 
mechanisms of cellular defense, indicate that the differences in 
the Raman signatures at the longer time points may be 
associated with differing degrees of cellular resistance.[47] 
C. Nanotoxicological screening 
 
Most of the strategies that have been proposed for the 
investigation of nanomaterials include the combinational use of 
toxicity assays, bio-imaging techniques, chemical and 
biochemical assays, to obtain information regarding to 
metabolic activity, membrane integrities, cellular viability and 
cell death mechanisms upon exposure. Cytotoxicity assays have 
been widely employed to determine cellular viability and also 
cell death rate in vitro. Electron microscopy (EM) and optical 
microscopy have been used for the visualisation of 
nanomaterials in cells. Confocal Microscopy (CLSM) has also 
been used for the visualisation of nanomaterials in cells with the 
aid of fluorescent labels.[51-54] High Content 
Analysis/Screening (HCA/HCS), has opened up new 
perspectives for toxicological assessment by providing 
multifaceted information with high sensitivity based on 
automated imaging of ‘phenotypic assay endpoints’. The 
technique has been used for in vitro toxicity assessment, animal 
disease models, drug discovery, neurobiology,[55, 56] cell 
signalling[57-59] and observation of biochemical changes.[58, 
60, 61] However, although conventional techniques have 
provided invaluable information regarding the interaction of 
nanomaterials with living systems, they remain limited in 
various aspects, such as the requirement of multiple labels and 
assays, interference of nanomaterials with the assay dyes,[62-
64] cost and also time required for the investigation. Raman 
microspectroscopy offers the potential to holistically screen 
uptake mechanisms of, and cellular responses to, nanoparticles, 
in vitro. 
The correlation between Raman spectral markers of carbon 
nanotubes (CNTs) and commonly used cytotoxicity assays has 
been studied by Knief et al. [17]. The studies of Dorney et al. [65] 
and Keating et al. [66] have shown the localisation of 
nanoparticles in cells and the use of multivariate analysis 
techniques to obtain more detailed information regarding to 
subcellular environment. As an extension of these studies, 
Efeoglu et al. demonstrated that the spectroscopic signatures of 
the nanoparticle environment in the cytoplasm can be tracked, 
as they are processed through endosomes (4hrs), to lysosomes 
(12hrs), to the endoplasmic reticulum (24hrs), for the case of 40 
nm non-toxic carboxyl-modified PSNPs, as shown in Figure 
6.[22] Expressed in terms of the loadings of the principal 
component which differentiates the nanoparticle local 
environment from control, the signatures demonstrate clear 
differences between the biochemical compositions, largely in 
terms of lipidic and protein content. 
For the case of 100 nm toxic PS-NH2, the biochemical 
composition of the cytoplasm as a whole is perturbed by the 
cellular responses to exposure, and can be monitored by Raman 
microspectroscopy. PS-NH2 are known to elicit acute toxicity as 
a result of oxidative stress in the endosomal and lysosomal 
pathway [22, 23, 65]. Figure 7 shows the loadings of PCA 
obtained from pairwise comparison of particle exposed cells (24 
hrs) and corresponding controls. Positive and negative features 
of the loadings relate to exposed and unexposed cells, 
respectively and the figure summarises spectral markers of 
acute toxic response in the cytoplasm, identified by Raman 
microspectroscopy. The predominant spectral marker of the 
toxic response in the cytoplasm is observed to be the ‘doublet 
band’ at 785 and 810 cm-1, which indicates a change in the 
cytoplasmic RNA as a result of ROS formation and the doublet 
band is observed in particle exposed cells even at low doses 
(EC25) and short exposure times (after 4 hrs).[23, 67, 68] The 
intensity of the band systematically and progressively changed 
as a function of dose and exposure time [23]. The doublet band 
was also observed in the biochemical features of Calu-1 cells 
following PS-NH2 exposure and progressively changed with 
extended exposure times [67]. When a second toxic nanoparticle 
model, PAMAM dendrimers, was introduced to the A549 cells, a 
similar trend to that for PS-NH2 is observed for the double peak 
at 785 and 810 cm-1, which, together with the results obtained 
from different cell lines and nanoparticle models, validates the 
changes in cytoplasmic RNA as a spectral marker of toxicity [68].. 
 
 
Fig. 6. Comparison of PCA loadings of 4, 12 and 24 hrs 
nanoparticle exposure data sets. Loadings are offset for clarity. 
The dotted line represents the zero ‘0’ point for each loading and 
an intensity scale of 0±0.1 is used for comparison. [22]. 
 
The changes in the doublet band, upon exposure to PS-NH2 
and PAMAM, are followed by concomitant and subsequent 
changes in the higher end of the fingerprint region, which 
provides information about protein (Amide I region) and lipid 
damage (1229 and 1438 cm-1). The band at 1438 cm-1, which has 
been identified upon PS-NH2 exposure, was also identified after 
exposure to PAMAM dendrimers and it has been observed to 
provide information regarding to lipotoxicity [23, 67, 69]. 
Notably, however, especially at extended exposure times, a 
significantly different evolution of spectral markers has been 
observed for the two different types of toxic nanoparticles, 
which can be attributed to different cell death mechanisms. 
Although the changes were more significant at long exposure 
times, the different response rates of the bands at early time 
points also provided information regarding the different cell 
death mechanisms. Cell death upon toxicant exposure can occur 
in multiple ways, most notably apoptosis and necrosis. The 
conventional apoptosis/necrosis assays use colorimetric 
identification based on cellular uptake of dyes and give 
information related to whether apoptotic or necrotic cell death 
has occurred. However, Raman microscopy not only provides 
information regarding whether the cell is apoptotic or necrotic, 
but also the biochemical path leading to this differentiation 
(Figure 8).  
Therefore, it can be concluded that Raman micro-
spectroscopy identifies signatures of the initiating toxic 
response and subsequent cellular dependent events, as a single, 
real-time assay and notably, brings new perspectives to 
determination of nanomaterial toxicity by identifying 
cytoplasmic RNA as a spectral marker, which is not normally 
identified by conventional toxicity assays. Moreover, the doublet 
band can be seen as the first strong spectroscopic response of 
oxidative stress. Although, it does not measure the ROS directly, 
it provides information about the response, which is a ROS 
related change in cytoplasmic RNA. The onset of ROS formation 
upon nanoparticle exposure has been observed to be within 2-6 
hrs [69, 70], and this initial stage of ROS dies away due to the 
action of intracellular antioxidants with a similar timescale [69]. 
In contrast, the doublet band is observed only after 8 hrs 
exposure to PS-NH2 and increases further with exposure time. 
Adopting the terminology of the Adverse Outcome Pathway 
methodology [71], upon exposure to a toxicant, the response 
begins with a molecular initiating event (MIE) which induces a 
cascade of consequent events. In the current context, the MIE is 
identified as the initial oxidative stress caused by the ingestion 
of the nanoparticles in exosomes and ultimately results in a 
change in cytoplasmic RNA, manifest as changes in the doublet 
peak of 785 cm-1 and 810cm-1. The study of Maher et al.[72] 
showed that the MIE shows particle dependency and induces 
cellular dependant events which can include, for example, 
changes in mitochondrial function, activation of caspases, and 
release of inflammatory factors. However, conventional and 
commonly used cytotoxicity assays use specific markers which 
can be defined as ‘endpoints’ and identify the toxicity as a 
function of half-maximal effective dose ‘EC50’. Therefore, these 
assays remain limited to provide information regarding to 
multiple events that occur concomitantly or consecutively inside 
the cell. Raman microspectroscopy shows signatures of this 
cascade as presence of spectral markers of initiating toxic event 
at low doses and short exposure times in the low wavenumber 
region (cytoplasmic RNA, indirect ROS), followed by 
concomitant changes (Protein and lipid damage as a result of 




Fig. 7. Spectral Markers of acute toxic response in the cytoplasm 
of A549 and Calu-1 cells after 24 hrs exposure to PS-NH2 and 
PAMAM nanoparticles. Positive and negative features of the 
loadings relate to exposed and unexposed cells, respectively. The 
750-830 cm-1 and above 1000 cm-1 region are indicated with 
highlights. Loadings are offset for clarity. The dotted line 
represents the zero ‘0’ point for each loading and intensity scale 




Fig. 8.  Spectral markers of cell death on cancerous (A) and non-cancerous (B) cell lines and cytotoxicity assays which are found to be 
related to the changes of these spectral markers. Loadings are offset for clarity. The dotted line represents the zero ‘0’ point for each 
loading and intensity scale of 0±0.05 is used for comparison. [65]. 
 
4. Discussion and Conclusions 
 
Technological advances have rendered Raman confocal 
microspectroscopy an increasingly routine benchtop laboratory 
technique for materials and process analysis. As an optical 
technique, it can provide submicron spatial resolution and can 
image biological cells and functions at a subcellular level, 
providing a wealth of information about the biochemical 
makeup, and changes to it due to exogeneous agents. The studies 
described herein were designed to explore the reproducibility of 
the characteristic spectroscopic signatures associated with 
cellular uptake of such agents and the subsequent response 
pathways.  
The results clearly demonstrate that the subcellular regions 
of the cell can be reproducibly differentiated based on their 
intrinsic biochemistry, and that the characteristic spectroscopic 
profiles are consistent across different cell lines. The subcellular 
localisation of chemotherapeutic agents or nanoparticles can be 
determined, and characteristic signatures of their initial 
chemical interactions can be established. The signatures are 
characteristic of the mode of action of the chemotherapeutic 
agent or nanoparticle, and, even in cases where the signatures of 
the agents themselves cannot be identified (at low doses or for 
weak Raman scatterers), these characteristic signatures can act 
as evidence of the action of the agent. These initial spectroscopic 
signatures can be differentiated from those of the subsequent 
cellular response pathways, which can specifically indicate the 
mode of cell death or cellular defence mechanisms.  
The studies of the model chemotherapeutic agent DOX 
demonstrate a clear added value of the technique, as they extend 
the current understanding of the mode of action by revealing the 
importance of the accumulation in the cell nucleoli, interacting 
with the RNA and initiating a cascade of cellular responses. In 
fluorescence based confocal microscopy, the nucleoli of DOX 
exposed cells appear dark, compared to the strongly fluorescent, 
DOX laden surrounding nucleus, and so it is understandable that 
such nucleolar based mechanisms have been overlooked, to 
date. Raman microspectroscopy reveals, however, that the 
nucleolar regions are equally laden with the drug, although it 
appears that the fluorescence is quenched due to the binding 
interactions in the dense region of the cell.  
The label free nature of the technique can thus be of great 
benefit for fundamental biochemical and cellular biological 
research. It enables, for example, the in situ monitoring of 
candidate drugs, of benefit to medicinal chemistry, and the 
ability to monitor the processes in live cells can provide a wealth 
of high content information for modelling approaches to 
pharmacokinetics and (nano) toxicology at a cellular level. The 
recent emergence of nonlinear Raman microspectroscopic 
techniques adds significantly to the potential in the field, as 
video rate, full spectrum analyses of areas of hundreds of 
microns have already been reported.[73] Applications in 
toxicological screening to guide regulatory processes, in vitro 
pre-clinical candidate drug screening to guide synthetic 
strategies, and even patient screening for drug 
sensitivity/resistance as the basis for companion diagnostics, 
can readily be envisaged.  
It should be noted, however, that a critical remaining 
challenge is that of data-mining the spectral information which 
is gathered. Label free, “what you see is what you get”, and the 
characteristic spectral signature of a response pathway contains 
information of all biomolecules within the sampling focus, 
whether they are involved or not. Specific signatures may 
dominate, however, and interestingly, the 785-810cm-1, nucleic 
acid doublet is prominent in both the studies highlighted here, 
albeit respectively in the nuclear regions for the action of drugs, 
and in the cytoplasmic region for nanoparticle toxicity, most 
likely due to conformational changes in the macromolecules. 
Differential signatures compared to control (e.g. PCA loading) 
provide the best visualisation of the characteristic changes due 
to an exogeneous agent. Regression analyses are appropriate for 
monitoring systematic evolutions, and although PLSR has largely 
been used in this work, more sophisticated techniques such as 
Multiple Component Regression, coupled with Alternating Least 
Squares approaches [74] may be more appropriate for response 
cascades. In all representations, the responses are spectrally 
multivariate, and can have contributions due to conformational 
changes, increases or decreases in local concentrations of a 
multitude of different biochemical constituents, including lipids, 
proteins, carbohydrates and nucleic acids. It is not possible, at 
present at least, to quantitatively analyse all these changes with 
molecular specificity. Nevertheless, this study indicates that the 
spectral signature of combined responses, the “spectralome”, is 
reproducible, consistent and translatable from different cell 
types and exogenous agents of similar modes of action.  
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